NCT06451471已完成不适用
Assessment of Serum Galectin-3 Level as an Indicator of Subclinical Inflammation in Patients With Familial Mediterranean Fever
Turkish League Against Rheumatism1 个研究点 分布在 1 个国家目标入组 154 人开始时间: 2021年5月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 154
- 试验地点
- 1
- 主要终点
- Serum Galectin-3 Levels
研究概览
简要总结
The goal of this observational study is to learn about the relationship between serum Galectin-3 levels and subclinical inflammation in patients with Familial Mediterranean Fever (FMF). The main questions it aims to answer are:
- Are serum Galectin-3 levels higher in FMF patients compared to healthy controls?
- Is there a positive correlation between serum Galectin-3 levels and Serum Amyloid A (SAA) protein levels in FMF patients?
Participants will:
- Provide blood samples to measure serum Galectin-3 and SAA levels.
- Complete a sociodemographic and clinical data form.
- Fill out the FMF Quality of Life (QoL) scale.
Researchers will compare FMF patients and healthy controls to see if there are significant differences in serum Galectin-3 levels and to determine the correlation between Galectin-3 and SAA protein levels in FMF patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Other
- 时间视角
- Cross Sectional
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •for the Patient Group:
- •Aged between 18 and 65 years,
- •Able to provide written informed consent for the study,
- •Diagnosed with Familial Mediterranean Fever (FMF) according to the Tel Hashomer criteria and not currently experiencing an attack (with at least 15 days since the last attack).
- •Inclusion Criteria for the Healthy Control Group:
- •Aged between 18 and 65 years,
- •Able to provide written informed consent for the study,
排除标准
- •Exclusion Criteria for the Patient Group:
- •Presence of known inflammatory diseases other than FMF,
- •Presence of known systemic, chronic, severe medical conditions,
- •Presence of active infection,
- •Conditions affecting cognitive functions such as mental retardation, delirium, dementia, epilepsy, and alcohol or substance use disorders,
- •Being pregnant or in the lactation period.
- •Exclusion Criteria for the Healthy Control Group:
- •Presence of known systemic, chronic, severe medical conditions,
- •Presence of inflammatory diseases,
- •Presence of active infection,
- •Conditions affecting cognitive functions such as mental retardation, delirium, dementia, epilepsy, and alcohol or substance use disorders,
- •Being pregnant or in the lactation period. -
结局指标
主要结局
Serum Galectin-3 Levels
时间窗: 2022
Comparison of serum Galectin-3 levels between FMF patients and healthy controls to determine if there is a significant difference.
次要结局
- Serum Amyloid A (SAA) Levels(2022)
- Clinical Variables(2022)
- Correlation Analysis(2022)
研究者
Oguzhan Lacin
Medical Doctor
Turkish League Against Rheumatism
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Galectin-3 Binding Protein in Cardiovascular Disease and Chronic Heart FailureCardiomyopathiesHeart FailureCoronary Artery DiseaseNCT01210157Heidelberg University373
进行中（未招募）
不适用
Association Between GalectiN-3 and pOSt-operative atrIal Fibrillation After Coronary Artery bypaSs GraftPost-operative Atrial FibrillationCardiovascular DiseasesPost-pericardiotomy SyndromeNCT06768528University of Sao Paulo General Hospital90
进行中（未招募）
不适用
se of galectin-3 as a blood marker for patients with Chagas disease.Chronic Chagas Disease with cardiac involvementB57.2RBR-5m6748Hospital São Rafael
已完成
不适用
Evaluation of Galectin-3 expression as a prognostic factor in non-small cell lung cancer patientson-small cell lung cancerJPRN-UMIN000026869Shiga University of Medical Science250
已完成
不适用
Serum Galectin-3 as a Marker of Human Papillomavirus InfectionHuman Papillomavirus InfectionNCT06005389Assiut University100